| Placebo | Pioglitazone |
---|---|---|
n | 11 | 12 |
Female (%) | 8 (72) | 7 (52) |
Age | 41 ± 14.1 | 39.4 ± 10 |
Age asthma onset | 21 ± 18.9 | 15 ± 11 |
Race | Â | Â |
 Caucasian | 9 (82) | 8 (66.6) |
 Black | 2 (18) | 4 (33.3) |
BMI | 43.5 ± 7.8 | 38.8 ± 6.8 |
Seasonal allergies (%) | 10 (91) | 10 (83) |
GERD (%) | 5 (45) | 7 (58) |
Depression (%) | 6 (55) | 7 (58) |
Asthma exacerbation in last 12Â months (%) | 7 (64) | 6 (50) |
Oral steroids in last 12Â months (%) | 4 (36) | 7 (58) |
Inhaled corticosteroid n (%) | 11 (100) | 12 (100) |
 High dose* (n) | 5 | 4 |
 Medium dose (n) | 4 | 8 |
 Low dose (n) | 2 | 0 |
Long acting beta agonist, n (%) | 9 (81.8) | 10 (83.3) |
Short acting beta agonist,n (%) | 11 (100) | 11 (92) |
FeNO (ppb) | 30.8 ± 28.4 | 27.6 ± 27.8 |
IgE (IU/ml) | 575 ± 544.7 | 291.2 ± 313.2 |
Juniper Asthma Control | 2.48 ± 1.30 | 1.75 ± 0.63 |
FEV1 (% pred pre BD) | 81.5 ± 15.2 | 82.3 ± 12.1 |
FVC (% pred. pre BD) | 85.3 ± 16.2 | 86.8 ± 13.7 |
FEV1/FVC (% pred. pre BD) | 94.9 ± 7.67 | 95.3 ± 11.12 |
FEV1 (% pred. post BD) | 88.1 ± 4.6 | 77.3 ± 25.1 |
FVC (% pred. post BD) | 88.3 ± 16.3 | 79.5 ± 27.6 |
FEV1/FVC (% pred. post BD) | 97.8 ± 7.82 | 90.9 ± 31.2 |